raltegravir-potassium and Diabetes-Mellitus

raltegravir-potassium has been researched along with Diabetes-Mellitus* in 1 studies

Other Studies

1 other study(ies) available for raltegravir-potassium and Diabetes-Mellitus

ArticleYear
Integrase strand transfer inhibitor-associated diabetes mellitus: A case report.
    International journal of STD & AIDS, 2017, Volume: 28, Issue:6

    Integrase strand transfer inhibitors (INSTIs) have become integral antiretroviral therapy (ART) agents for treating HIV infection. We report the case of a 44-year-old male with a history of hemophilia A who developed diabetes mellitus four months after switching from abacavir, lamivudine, and efavirenz to abacavir, lamivudine, and raltegravir. Hemoglobin A1C normalized without further need for exogenous insulin after raltegravir was switched back to efavirenz. In this case report, we will review a possible mechanism for INSTI-induced hyperglycemia and/or diabetes mellitus.

    Topics: Adult; Diabetes Mellitus; Dideoxynucleosides; Drug Combinations; Glycated Hemoglobin; HIV Infections; HIV Integrase Inhibitors; Humans; Lamivudine; Male; Raltegravir Potassium

2017